docproteos biotech
download 
Report Transcription
proteos biotech
Spanish White Biotech Pipeline Spanish White Biotech Pipeline Products, Process and Technology Code 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS 3P BIOPHARMACEUTICALS Biomaslinic Biomedal Biomedal Biomedal Biomedal BIOTMICROGEN Gaiker Gaiker Gaiker Gaiker Gaiker Gaiker Gaiker Gaiker GH Genhelix GH Genhelix GH Genhelix GH Genhelix GH Genhelix GH Genhelix 3P-Protexp 3P-Product 3P-Fermen 3P-Mammal 3P-MCB/WCB 3P-GMP 3P-MAL 3P-Hor 3P-BIO 3P-Hum 3P-TC GHL - MIC GHL - MAM GHL - CCUL GHL- PUR GHL - PROTO GHL - PROD T T T T Ps Ps T Ps Ps Ps T P P P P T Ps P T T T T P P T T T Ps Ps T Ps GH GH GH GH GH GH GH GHL - BIOSIM GHL-11001 GHL-11002 GHL - OPT GHL - VACC GHL - AD GHL - TT T P P T T/Ps T T CASCADE LYTAG-2-PHASE nLZ4 GLUTENTOX BMG - LFP Genhelix Genhelix Genhelix Genhelix Genhelix Genhelix Genhelix The wide number of associates makes ASEBIO the most appropriate meeting platform to face up to the challenges of developing the Biotechnology sector in Spain. www.asebio.com ASEBIO, the Spanish Bioindustry Association, encompasses over 160 firms, associations, foundations, universities, technology and research centers which carry out activities directly or indirectly related to Biotechnology. GP-PHARM GP-PHARM IGEN BIOTECH Instituto Biomar The Spanish Bioindustry Association Type* Company DNA kit IB-Anlisis GC-S50 GC-Bio-CAT GC-S51 GC-Bio-OA02 GC-S77 GC-Bio-DTFF GC-Bio-DF GC-Bio-F GC-Bio-TFT GC-Bio-DAP GC-Bio-AP GC-Bio-SRC GC-S79 Bio-Che Sol-S75 GC-S76 P/T P/T P T P P P Ps P P P P P P P T P T P P P Ps Ps P P Ps Ps T P P T IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT IUCT Laboratorios LETI NEURON BioIndustrial ARQUEBIO IUCT IUCT IUCT IUCT IUCT SANIFIT SANIFIT ARQUEBIO MicroBiOil ¨ C2B-PESA GC-S78 GC-S77 Bio-Can Bio-vir CG-Bio-MB ASB-01 ASB-01 C2B ARQUEBIO ARQUEBIO ARQUEBIO PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH ARQUEBIO ARQUEBIO ARQUEBIO ARQUEBIO Biomedal Biomedal BIONATURIS C2B-PBEA B2B-MB-CA B2B-EP-CA PROTEOS-PPS PROTEOS-MENC PROTEOS-RCE PROTEOS-RKE PROTEOS-RPROT PROTEOS-CAI C2B-MO-Aq C2B-MO-Mn C2B-MM-Tr C2B-MR-RC PROTEO-STAMP HIS-TAG-2-PHASE FLYLIFE CLEAN BIOTEC Instituto Biomar PROTEOS BIOTECH SENSIA X-Pol Biotech X-Pol Biotech ARQUEBIO CIBER-BBN CIBER-BBN CIBER-BBN Halodepur IB-Agricultura PROTEOS-BESE Biosensor X-Pol Biotech X-Pol Biotech C2B-PCA BBN-Device BBN-NP BBN-Cell Biol IDEN BIOTECHNOLOGY IUCT Laboratorios LETI LEITAT IB-PB Bio-13P T P Ps T NEURON BioIndustrial NEURON BioIndustrial PROTEOS BIOTECH CIBER-BBN MICROBIOTOOLS¨ SCR-Mtb PROTEOS-MEM BBN-Device T T Ps P ARQUEBIO CIBER-BBN B2B-HM-CA BBN-Device P P PROTEOS BIOTECH PROTEOS BIOTECH ARQUEBIO ARQUEBIO ARQUEBIO ARQUEBIO BIOTMICROGEN CLEAN BIOTEC Instituto Biomar IUCT IUCT Laimat Soluciones Cientfico Tcnicas NEURON BioIndustrial NEURON BioIndustrial IUCT Instituto Biomar Instituto Biomar Laimat Soluciones Cientfico Tcnicas BioSerentia BIOMASSBOOSTER PROTEOS-PPMW PROTEOS-PPDA B2B-PA N4B-MP N4B-MP-He B2B-HA BMG - PC331 Phytodesal IB-Cosmtica Bio-LIP Bio-OA03 TriBioPlast ¨ OMG3-SCO Bio-K3 IB-Enologia IB-Alimentacin SQ-NH BMB - 303 Ps Ps P P P P P T P P P Ps Ps Ps P P P T T BioSerentia BIOMASSBOOSTER BMB - 707 T Instituto Biomar NEURON BioIndustrial CIBER-BBN IB-Acuicultura NST-Pkt BBN-BIOMOL T Ps T CIBER-BBN CIBER-BBN BBN-BIOMARK BBN-BIOMATER T T Instituto Biomar LEITAT LEITAT ARQUEBIO IDEN BIOTECHNOLOGY LEITAT LEITAT LEITAT PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH PROTEOS BIOTECH ARQUEBIO CIBER-BBN PROTEOS BIOTECH BIOMOL-INFORMATICS IB-Biodisel Ps T T Ps T Ps Ps Ps Ps Ps Ps Ps T T Ps T CIBER-BBN BBN-AGN-CONTR T CIBER-BBN BBN-FUN-NP-BIOM T PROTEOS BIOTECH ISC III ISC III ISC III LEITAT LEITAT LEITAT LEITAT LEITAT PROTEOS-BS (*) P= Product Ps= Process N4B-CB IB-MB PROTEOS-BESB PROTEOS-PPDET PROTEOS-MBP PROTEOS-BPEFA N4B-RP BBN-CONTRAGENT PROTEOS-HG Ps P P Ps Ps P P P P Ps Ps Ps Ps Ps P Ps Ps P Ps P P P Ps P Ps/P Ps P T T T Ps/P Ps/P Ps Ps T Indication Basic R+D Applied R+D Protein expression systems Production of Recombinant Proteins Bacterial , fungi and yeasts fermentation Manufacture and purification of proteins from mammalian cells Creation and qualification of cell banks: MCB and WCB Culture and maintenance of bank cells under GMP conditions Production of monoclonal antibodies Production of vaccines, growth hormones Production of Biosimilars Human cells in culture Development banks crops and human cells for cell therapy Method for obtaining maslinic acid and hydroxitirosol from olive by products Bacterial expression system Protein separation and purification Cost effective ligand for antibody purification Methods for the detection of the most immunogenic fraction of gluten Lactic fermentation Active packaging Biodiesel production Ag-Ab union/DNA based biosensors development Biodetergency Bioremediation Biofunctional nanoparticles sintesis Biopolimers development CO2 Supercritic Production of Microbial recombinant proteins Production of biologicals expressed in mammalian cell lines Microbial and Mammalian cell culturing Recovery and purification of MABs and other recombinant proteins Single use technology application to bioprocesses (Protoplant) Recombinant Proteins and Monoclonal antibodies (MABs) production with single use technology implementation Biosimilar MABs development platform GHL-11001 MAB Biosimilar GHL-11002 MAB Biosimilar Cell culture optimization for cell and gene therapies Production of biological vaccines through single use equipment Analytical development of bioprocesses Process development, scale-up, scale-down, and technology transfer of Bioprocesses. (USP & DSP) Micro nanospheres for release injectable products of peptide Liposomes for release of injectable oncological products Pre-natal Quick DNA Extraction Kit Determination of antibiotics in milk Second generation biodiesel Biocatalysts: Oxidses, Phosphorylase New solvent from renewable materialas for synthesis of APIs Biosynthesis of Exolysaccharides New solvent from renewable materials from DMA Biosynthesis 2-dexosytrifluorotimidina / Anticancer and Antiviral 2-deoxy-5-fluorouridine / Anticancer / Colon & Pancreas 5-fluorouridine / Anticancer / Colon & brust trifluorothymidine / Antiviral Ophtalmology / Herpes Cornea 2,6-diaminopurine deoxiriboside / Anticancer 2,6-diaminopurine riboside / Antiviral / Anticancer Discovery/screening of new microorganism for biotransformations Solvents from renewable materials for the biodiesel sector Substitution of chemical processes for bioprocesses New solvent from renewable materialas for metal degreasing New solvent from renewable materialas for metal degreasing Production of protein extracts / allergens Biodiesel 2G production Biocatalysis platform for esterification of organic compounds New solvent from renewable materials for Crop protection New solvent from renewable materials for Paint and barnishes Biotechnological synthesis of anticancer drugs Antivial drug biobased synthesis Molecular biology: genetically modified microorganism Treatment of dental calculus - Mouthwash Treatment of dental calculus - Gel Screening platform for microbial and enzymatic chemical reactions for bioprocess aplications Biocatalysis platform for oxydation of methyl groups in aromatic substances Modified biopolymers for cosmetic applications Exopolysaccharides for cosmetic applications Protein Purification System Microencapsulation Recombinant collagenolytic enzymes Recombinant keratinolytic enzymes Recombinant proteases Cosmetic active ingredients Microbial oxydation of anthraquinones Microbial oxydation of methyl naphtalenes Microbial modification of triterpenes Microbial resolution of racemic compounds Immovilization and shipment of fusion proteins Aqueous two phase separation of histagged proteins CDMO. MVB, WSVB, upstream development, downstream development, analytical development, scale-up Biodepuration process of hipersaline wastewater Microbial Biopesticides Bacterial expression system in E. coli Biomolecular interaction analysis and the presence of chemical compounds MagniPhi: Phi29 DNA Polymerase Human DNA Pplymerase mu Biocatalysis platform for aldole condensations Thermomagnetic applicator device for treatment of Nervous System Alterations Procedure for obtaining stable metallic nanoparticles Optimized histological method for thepreservation of epitopes and cellular architecture of vertebrate tissues Technologies to improve crops Biosynthesis of 1,3-propanodiol Protein Purification In Vitro testing technologies for cosmetics, foods, pharma (ADMETOX, efficacy,safety) Biotransformation platform Metabolite screening platform Microemulsification Sensing contact lens, system for the noninvasive monitoring of the intraocular pressure and method for its measure Halomuccines for cosmetic applications Micro-chamber device for cellular culture monitoring by nuclear magnetic resonance Proteolytic proceses - meat waste Proteolytic proceses - dairy applications Polyhydroxyalkanoates of microbial origin platform Multifunctional proteins for drug delivery Multifunctional proteins for healthcare end uses Hyaluronic acid of microbial origin platform Probiotics strain with inmunomodulation capacity Soil desalination with salt phytoaccumulators Extract antifungal Biocatalysts: Lipases Expolisacarido OA03 Microencapsulation, peptides, proteins, essential oils, active principles Biopolimers production Production of Omega-3-Rich Oil by fermentation Menadione (vitamin K3) Production of O. oeni (malolactic fermentation) Microbial preservative Sensors,Antibiotics, toxics present in food, clinical toxicology, early diagnosis Propietary Genetic Engineering Platform to increase biomass from microalgae to yield biofuels and high valued products Propietary Genetic Engineering Platform to increase biomass from higher plants and crops to yield biofuels and high valued products Microbial control farms Biosynthesis of new poliketides derivatives Design and "a la carte" production of Biomolecules (Proteins, Antibodies and Peptides) Biomarkers with direct clinical application Production & Characterization of Functionalized Biomaterials and Scaffolds for Regenerative medicine Biodiesel Production Production of monoclonal antibodies and recombinant proteins Protein purification Chemical bioconjugation of biopolymers with APIs Technologies to improve micro-organisms Bioprocess for textile processing Enzymatic improvement of fats and fat valoristaion Substitution of chemical processes for bioprocesses Bacterial expression system in Bacillus Megaterium Proteolytic proceses - detergents applications Microbial biogas production Biocatalysis processes - Esssential fatty acids Recombinant proteins for gene therapy Contrast agents for MRI Hydrogel Generating 3D computer models for bacterial protein polymers as scafolds for nanowires. Contrast agents based on nanoparticles with magnetic and paramagnetic properties Getting new compounds (therapeutic nanoconjugates) with therapeutic activity and biocompatible and functionalized polymeric materials to produce therapeutic substitutes (mesh) and implants Biosimilars Method and Kit for Detecting the Hepatitis E Virus (HEV) Obtaining human mesenchymal stem cells from peripheral blood (PB-MSC) Production of monoclonal antibodies Enzyme immobilization Microencapsulation of active ingredients and enzymes Enzymatic synthesis of prebiotic ingredients Obtention of protein hydrolysates Antimicrobial/antifunagl screening T= Technology. BASED ON DATA PROVIDED BY ASEBIO ASSOCIATED ORGANIZATIONS, MAY 2011 www.asebio.com Ready for exploitation Industrial Scale up Available 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 Technology transfer in process Patent 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 Prototype 4 4 4 4 4 4 i.p. 4 4 4 Prototype 4 4 4 4 Prototype 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 Requested 4 4 4 4 4 4 4 4 Requested 4 Requested 4 Requested 4 4 Only special preparations 4 4 4 4 Prototype 4 4 Requested 4 4 4 4 4 4 4 4 Requested 4 4 i.p. 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 Requested 4 Requested PROTEOS BIOTECH Recombinant kera.noly.c proteases – Kera.nase Summary PROTEOS Biotech Kera2nases are wide spectrum enzymes with specific ac2vity to disulfide bonds with very high affinity to kera2n. Kera2nase is produced under recombinant condi2ons and purified by chromatography. T h e y p r o c e e d f r o m B a c i l l u s licheniformis (PWD) and produced in E. coli and B. megaterium. Kera2nase has been adapted to laboratory and cosme2c condi2ons (microencapsulated) Applica-ons Patent applica-on number Priority date References Pure100 Kera2nase is mainly used in cell cultures and cell dissocia2on. The main market for these proteases are the laboratories in research ins2tutes or hospitals. PROTEOS BIOTECH Recombinant proteoly0c enzymes – Sub0lisin DFE Summary Applica-ons Patent applica-on number Priority date References PROTEOS Biotech Sub1lisin‐DFE is a wide spectrum enzyme with great affinity for a high spectrum of substrates and synthesized by the microorganism in pre‐ pro‐protease form . These proteases have a great purity on having been produced under recombinant condi1ons and purified by affinity chromatography. O u r S u b 1 l i s i n p r o c e e d s f r o m B a c i l l u s amyloliquefaciens and produced inE. coli. and B. megaterium. All the Sub1lisins have been adapted to laboratory and cosme1cs (microencapsulated) work condi1ons . Pure100 Sub1lisin DFE is mainly used in cell cultures and cell dissocia1on. The main market for these proteases are the laboratories in research ins1tutes or hospitals. PROTEOS BIOTECH PROTEOS BIOTECH Recombinant collagenoly/c proteases – Collagenase G and Collagenase H Summary Applica-ons PROTEOS Biotech Collagenases are extremely pure proteases, produced under recombinant c o n d i > o n s a n d p u r i fi e d b y a ffi n i t y chromatography. Our Collagenases originate from Clostridium hystoli>cum and are produced in E. coli and B. megaterium. They have been tested in cell culture and adapted to laboratory work condi>ons. Pure100 Collagenases are mainly used in cell cultures and cell dissocia>on. The main market for these proteases are the laboratories in research ins>tutes or hospitals. Recombinant collagenoly/c proteases – Pz‐Pep/dase Summary Applica-ons Patent applica-on number Patent applica-on number Priority date Priority date References References Pz‐Pep&dase is an enzyme of high affinity to collagen oligopep&des. PROTEOS Biotech Pz‐Pep&dase is considered essen&al for the degrada&on of collagen in collabora&on with collagenoly&c enzymes. We produce pure recombinant Pz‐Pep&dase using affinity chromatography. Our enzyme proceeds from Bacillus licheniformis(PWD) and produced in E. coli. PROTEOS Biotech Pz‐ Pep&dase has been adapted to laboratory condi&ons and is suitable for cell culture studies. Pure100 Pz‐Pep&dase is mainly used in cell cultures and cell dissocia&on. The main market for these proteases are the laboratories in research ins&tutes or hospitals. INDUSTRIAL GROUP PROTEOS BIOTECH Cosme&c ac&ve ingredients – KERATOCLEAN® PB Summary Applica-ons Patent applica-on number KERATOCLEAN® PB is an ac3ve ingredient consis3ng of a microencapsuled enzyme of biotechnological origin. This enzyme has mild kera3noly3c effect (exfolia3on, smoothing) and s3mulates the turnover of epidermal cells (regenera3ng ac3vity). The main component is an extract of purified KerA Kera3nase which promotes the elimina3on of excess corneocytes. K E R ATO C L EA N ® P B i s a revo l u 3 o n a r y a c 3 ve microencapsuled kera3noly3c enzyme which consists of natural substances (without any acids) ac3ng at well tolerated pH 8, much closer to the epidermal physiological pH. KERATOCLEAN®PB is especially recommended for the following condi3ons: nail infec3ons, skin firmness, exfoliant, hirsu3sm, acne, keratosis pilaris, eczema, psoriasis, athlete's foot or calluses. The main market for our product are the cosme3c companies interested in incorpora3ng our ac3ve ingredient in their formula3ons or distributors of cosme3c ingredients. KERATOCLEAN® PB is a registered mark. Cosme&c ac&ve ingredients – RENOVENZYME® PB Summary Applica-ons Patent applica-on number Priority date Priority date References References RENOVENZYME® PB is an an1‐cellulite ac1ve ingredient consis1ng of a microemulsion of enzymes of biotechnological origin. These enzymes have mild collagenoly1c effect (mild hydrolyza1on of collagen) and s1mulate the turnover of new collagen (regenera1ng ac1vity). The main component is an extract of purified Collagenases which promotes the renova1on of amorphous collagen. RENOVENZYME® PB is especially indicated for the cellulite treatment. RENOVENZYME® PB is especially indicated for the cellulite treatment. The main market of our product are the cosme1c companies which are interested in incorpora1ng our ac1ve ingredient in their formula1ons or distributors of cosme1c ingredients. RENOVENZYME® PB is a registered mark. NEURON OMG3‐SCO Summary Applications Patent application number Priority date References Neuron BioIndustrial has developed a technology to produce high quan77es in omega‐3 fa<y acids rich‐oils from the microalgae belonging to its exclusive collec7on. E i c o s a p e n t a e n o i c a c i d ( E P A ) a n d Docosahexaenoic acid (DHA) are the most valuable omega‐3 fa<y acids and offer many benefits to human health. Both acids decrease triglyceride levels and the possibility of suffering from arrhythmia. DHA is also an essen7al compound in the central nervous system and plays a key role in child development These omega‐3 fa<y acids rich‐oils can be added to food formulas or nutraceu7cal products. NEURON TriBioPlast® Summary Applications Patent application number Priority date References TriBioPlast® is a biotechnological way of obtaining bioplas7cs with mul7ple applica7ons. Neuron BioIndustrial, has selected micro‐organisms capable of producing and accumula7ng more than 60% of their dry weight as polyhydroxyalkonates (PHAs) from different carbon sources. Among the raw materials studied are raw glycerin ,glucose, molasses, by‐products from the olive industry and different types of faKy acids (C6 to C14 in chain length). By using these different carbon sources or their combina7ons Neuron BioIndustrial has obtained more than 15 different biopolymers. PHAs are biodegradable because they are metabolized by a wide variety of micro‐organisms to finally produce carbon dioxide and water. Furthermore, most of these polyesters are biocompa7ble. Consequently these biopolymers may have a wide range of medical‐pharmaceu7cal applica7ons, such as in transplants, suturing, osteosynthe7c materials and so forth. Non Non LEITAT Subs%tu%on of chemical processes for bioprocesses Summary Applications The proposed technology is based in the evalua%on of proper biocatalysts for the subs%tu%on of chemical processes by bioprocesses. These biocatalysts (enzymes and or microorganisms) can be commercial or specially developed to a subs%tute a specified process. Once the specific biocatalyst is selected the bioprocess can be developed at a lab scale. Bioprocesses run at moderate condi%ons compared to chemical processes, are more selec%ve for the substrate and products and can result in a beAer reac%on yield and lower waste genera%on. Also they do usually consume less energy than chemical processes. – C hemical sector: esterifica%ons, epoxida%ons, oxida%ons… – C osme%c sector: ac%ve ingredient produc%on, produc%on of bioemulsifiers… – Food sector: fats and oils valoriza%on, fruit squeezing improvement, pec%n degrada%on… – Waste water treatment: tex%le effluent decolora%on, hydrogen peroxide abatement… Patent application number Priority date References Bioprocesses in the food industry . MEETING REPORT .CURRENT SCIENCE, VOL. 91, NO. 5, 10 SEPTEMBER 2006 The use of enzymes in the chemical industry in Europe . Current Opinion in Biotechnology 2002, 13:359–366 LEITAT Generación de an+cuerpos monoclonales Summary Applications Patent application number Priority date References Generamos an+cuerpos monoclonales a la carta de acuerdo con las necesidades del cliente. El diseño de todo el proceso; que incluye las etapas de inmunización, cribado, clonación y caracterización; se define conjuntamente con el cliente, para obtener un producto con las caracterís+cas deseadas. Desarrollo de biosensores Desarrollo de kits de diagnós+co Aplicación en inves+gación biomédica. Sectores: alimentación, química industrial, cosmé+ca, salud LEITAT Obtention of protein hydrolysates Summary Applications Patent application number A large number of biologically ac1ve pep1des has been isolated from bacterial, fungal, plants and animal sources. Leitat, in collabora1on with a partner, can apply virtual screenings (in silico) for iden1fying new ac1ve pep1de for a desired func1onality. A>erwards, Leitat can op1mize the hydrolisis of protein frac1on from different sources including sub‐products of industrial processes (combining enzyma1c and physic treatments) for enriching the protein hydrolysate in the ac1ve pep1des. • Valoriza1on of sub‐products of industrial processes • Development of new func1onal foods (with many different func1onali1es) • Development of new ingredients for animal fed • Development of new ingredients for cosme1cs No patent presented Priority date References Ahhmed et al 2010. A review of meat protein hydrolysates and hypertension. Meat Sci 86:110‐8 Gill et al 1996. Biologically ac1ve pep1des and enzyma1c approaches to their produc1on. Enzyme and Microbial Technology 18: 162‐183 LEITAT Microencapsulation of active ingredients and enzymes Summary Applications Patent application number A microcapsule is a small sphere with a uniform wall around it. The material inside the microcapsule is referred to as the core, internal phase, or fill, whereas the wall is some8mes called a shell, coa8ng, or membrane. Different encapsula8ng agents, such as carbohydrates, celluloses, gums, lipids and proteins (gela8n, whey proteins) can be used based on the characteris8cs of the core ingredient, the matrix of the product and the applica8on. Different technologies have been developed for encapsula8ng ac8ve ingredients, such as spray drying, lyophiliza8on, extrusion and liposomes. Microencapsula8on has been applied in food and cosme8c industries for preserving the ac8ve ingredients from the adverse condi8ons of product produc8on (temperature, humidity, pH), to avoid altering organolep8c characteris8cs of , or to controlling the release of the core ingredient. No patents presented Priority date References Gautam A, Patrick M, Dagerath ML (2007) patent code: WO2006058634 Kuang SS, Oliveira JC, Crean AM (2010) Microencapsula8on as a tool for incorpora8ng bioac8ve ingredients into food. Crit Rev Food Sci Nutr 50:951‐68 LEITAT LEITAT ADME and toxicity Skin biology/care Summary Applications Our in vitro systems are of special value to support marke8ng claims to provide insights into cell molecular mechanisms. These systems are useful at early stages of product development, as an alterna8ve to animals, and prior to in vivo assessment in human volunteers. Some of our assays include an8‐aging, vitalizing, firmness, an8‐oxidant effect, elas8city, an8‐inflammatory effect, moisturizing, skin repair, photoprotec8on, r e c o n s t r u c 8 o n , c a l m i n g e ff e c t , u s e o f reconstructed 3D human 8ssues, irrita8on and corrosion tes8ng, acute toxicity, citotoxicity, phototoxicity, genotoxicity, teratogenicity and skin sensi8za8on. Studies are conducted following Good Laboratory Prac8ces, as well as, OECD and ECVAM test procedures. Assays and models can cover both safety and efficacy tes8ng of raw materials or final products for Cosme8c and Dermopharma industry. We can also provide customized research and scien8fic consul8ng to cosme8c industry. Summary In vitro Absorp8on, Distribu8on, Metabolism and Toxicity assays following rigorous quality standards under FDA guidelines and GLP standards. Cost‐effec8ve methodology in comparison with in vivo studies. Genera8on of a lot of informa8on within a short 8me during early stages of development, as well as evalua8on of new molecules and ac8ve ingredients. Problem solving in drug metabolism to support drug discovery and development processes using, different in vitro systems. Applications Research focalized in Mechanisms of ac8on, Screening and op8miza8on, as well as, Compound and NCEs (“New Chemical En88es”) Proof of Concept, for Pharmas, Food indsutry, Chemical industry, Medical devices, CROs References • Schroeder K et al.. Report from the EPAA workshop: In vitro ADME in safety tes8ng used by EPAA industry sectors. Toxicol In Vitro. 25:589‐604, 2011. • Gómez‐Lechón MJ et al. In vitro evalua8on of poten8al hepatotoxicity induced by drugs. Curr Pharm Des. 2010;16(17):1963‐77. • Lahoz A et al. In Vitro ADME Medium/High‐Throughput screening in drug preclinical development. Mini‐Reviews in Medicinal Chemisry 6:1053‐62, 2006. LEITAT Enzyme immobiliza-on Summary Applications The u-liza-on of enzymes as biocatalysts offers several advantages: bioprocesses run at moderate condi-ons, are more selec-ve, can result in a be=er reac-on yield and lower waste genera-on and consume less energy than chemical processes. However enzyme u-liza-on is usually more expensive than other chemical catalysts. Therefore enzyme immobiliza-on can be used to allow their recovery and reu-liza-on. Also immobiliza-on can improve enzyme stability. The proposed technology includes: ‐ s upport selec-on for the enzyme immobiliza-on (commercial materials or specifically synthesized ‐ both micro and nanopar-cles‐) ‐ Development of enzyme immobiliza-on protocol ‐ Immobilized enzyme characteriza-on ‐ Development of bioprocesses with immobilized enzymes – C hemical sector: esterifica-ons, epoxida-ons, oxida-ons… – C osme-c sector: ac-ve ingredient produc-on, produc-on of bioemulsifiers… – Food sector: fats and oils valoriza-on, fruit squeezing improvement, pec-n degrada-on… – Waste water treatment: tex-le effluent decolora-on, hydrogen peroxide abatement… Patent application number Priority date References Understanding enzyme immobilisa-on. Chem. Soc. Rev., 2009, 38, 453‐468 LEITAT Enzymatic synthesis of prebiotic ingredients Summary Applications Patent application number A prebio)c is a non‐viable food component that confers a health benefit on the host associated with modula)on of the microbiota. They are present in vegetables and other fruits but can be also produced by enzyma)c reac)ons. Poten)al prebio)c proper)es can be studied using a full model of gastrointes)nal tract diges)on and pure culture studies with relevant prebio)c, enteric and pathogenic microbial strains or using a colonic model consis)ng of in vitro fermenta)on systems with representa)ve human gut bacteria. Moreover, the puta)ve beneficial effect on ac)vity of the gastrointes)nal microbiota will be determined by measuring the produc)on of short chain faBy acids as well as the produc)on poten)ally harmful proteoly)c products. Leitat technology include prebio)c isola)on from different sources, including sub‐products of industrial processes, enzyma)c modifica)on if needed for improving their func)onality and demonstra)on of prebio)c proper)es • Development of new func)onal foods for improving gastrointes)nal health • Development of new ingredients for feed (for improving animal performance) • Valoriza)on of sub‐products of industrial processes No patent presented Priority date References Mandalari et al (2010) In vitro evalua)on of the prebio)c proper)es of almond skins (Amygdalus communis L.) FEMS Microbiol LeB 304: 116‐122 Maiorano et al (2008) Microbial produc)on of fructosyltransferases for synthesis of pre‐bio)cs. Biotechnol LeB. 30:1867‐77 LEITAT Enzyma'c improvement of fats and fat valoriza'on Summary Applications The proposed methodology is based in the u'liza'on of enzymes for the directed modifica'on of triglycerides to improve their profile or performance. The technology can also be used for the valoriza'on of fats and oils into valuable products such as emulsionants for different sectors (detergency, cosme'cs…) ‐ Fat profile improvement ‐ Saturated fats reduc'on ‐ Valoriza'on of fats and oils into valuable products Patent application number Priority date References Enzyma'c Interesterifica'on:Process Advantages and Product Benefits. Palm Oil Developments 398: 7‐10 LEITAT Bioprocess for tex-le processing Summary Applications Two processes for the enzyma-c co8on finishing treatment have been developed. One is based on a semicon-nuous process and the second is based on the u-liza-on of a termoresistent enzyme for co8on finishing and bleaching in a single step. These processes allow for bath and chemicals reu-liza-on therefore improves tex-le industry environmental impact and reduces the finishing costs. The developed enzyma-c process can be applied in: ‐ The co8on finishing process ‐ For biotechnology companies developing new enzymes for tex-le processing. The developed process can be used to test and compare new developments with commercial products. Patent application number Priority date References METODOLOGIAS DE TRATAMIENTO DEL ALGODÓN CON PROCESOS ENZIMÁTICOS EN SUSTITUCIÓN A LOS CONVENCIONALES. Revista de Química e Industria tex-l. (2010),198:36‐43. LEITAT Antimicrobial/antifungal screening Summary The an'microbial and an'fungal ac'vi'es of different extracts against microorganisms that may be important in different fields (skin care, oral health, human or animal pathogens, food industry, …) can be tested. The an'microbial and an'fungal ac'vi'es will be assessed by performing a disk diffusion assay. The an'microbial or an'fungal ac'vity of most ac've compounds will be also validated applying ISO and UNE standards. Applications Patent application number • Valoriza'on of industrial processes sub‐products • Development of new ingredients for cosme'c and pharmaceu'cal industries (an'‐acne, oral health, new an'bio'cs, …) • Development of new products for food industry (natural preserva'ves for reducing food spoilage, increasing food security) • Development of new an'microbial/an'fungal compounds for func'onal tex'les ( for example clothes for medical applica'ons) No patent presented Priority date References UNE‐EN‐1275: An'sép'cos y desinfectantes químicos. Ac'vidad fungicida básica UNE‐EN‐1276: An'sép'cos y desinfectantes químicos. Ensayo cuan'ta'vo de suspensión para la evaluación de la ac'vidad bactericida de los an'sép'cos y desinfectantes químicos u'lizados en productos alimen'cios, en la industria, en el hogar y en la colec'vidad LAIMAT Microencapsula-on technologies Summary Applica-ons Patent applica-on number Development of technologies of microencapsula-on for drugs and chemical products such as cosme-cs, tex-les and new materials. The main ADVANTAGES of our microencapsula-on technologies are: • Increase of the STABILITY against extreme condi-ons • Controlled DELIVERY of ac-ve principles, pigments, colorant, scents, etc. • Avoids loss of vola-le compounds (scents or perfume in cosme-cs, etc.) • Disguises bad smells Our microencapsula-on technologies can be tailored for different applica-ons, it depends on the need that has to be solved so it can be applied in different sectors such as cosme-c, pharma, agro food and materials. At the moment we are developing: • Micro organism microcapsules for self healing materials. • Ac-ve principles microcapsules for agriculture use. • Microcapsules of natural substances with an-bacterial and an-fungal proper-es for alimentary use. Nº de la patente en caso de que haya, incluso si no está publicada sería importante ponerlo Priority date Fecha de prioridad de la patente, importante para conocer la “edad” de la patente References Si hay referencias en forma de arTculos, patentes o cualquier otro documento incluirlas aquí, es importante para que las empresas analicen la tecnología LAIMAT Electrochemical sensors Summary Applications Patent application number Development of a new technology based in the use of electrochemical sensors for the detec9on of substances of interest in the fields of food safety, clinic toxicology and legal and forensic medicine. In short, these new sensors can be a revolu9on in analy9c chemistry because with the op9miza9on of this technology we can arrive at personalized sensors, with great compe99ve advantages: • Easy use technique • Quick and real 9me analysis • No need of specialized personnel • High sensibility and specificity • Portability and possibility of in situ analysis • Miniaturiza9on and monitoring possibility • Low cost when compared to actual technologies At the moment we are op9mizing our technology for con9nuous monitoring in the field of Food safety . But our technology has different fields of applica9on that are being developed: • Food safety: detec9on of toxics present in food such as biogenic amine, pes9cides, an9bio9cs, etc. • Clinical toxicology: abuse drugs, toxics and medicines determina9on in biological fluids (design drugs, s9mulants, opiate, etc.) • Early diagnosis: biomarkers detec9on for early diseases diagnosis. Nº de la patente en caso de que haya, incluso si no está publicada sería importante ponerlo Priority date Fecha de prioridad de la patente, importante para conocer la “edad” de la patente References Si hay referencias en forma de arXculos, patentes o cualquier otro documento incluirlas aquí, es importante para que las empresas analicen la tecnología GP‐PHARM MICROSPHERES GP Pharm has experience obtaining microspheres through out different technologies such as: Double emulsion and coacervation Summary Platform based on the use of PLGA microspheres containing triethyl citrate to modulate a sustained drug release. • Enhanced control during release phase • Enhanced sustained release during the whole treatment • Enhanced pharmacologic effect • Decrease of the requested dose per administration unit This technology allows to obtain inyectable depot formulations with controlled drug delivery system from one week to six months. • Agonists LHRH (leuprolide, triptorelin, goserelin) • New active peptides Applications • Peptides somatropin release inhibiting factor SRIF or GHIH (Octreotide LAR, MAR). • Other molecules (Risperidone) Patent application number Priority date References Several patents have been awarded for technology platform: WO-01/43724 A1. ES2169980 B1, ES2194793 T3,ES2144357 B1, ES2217717 T3. ES2169980 B1 (01/11/03), ES2194793 T3 (01/12/03), ES2144357 B1 (16/12/00), ES2217717 T3 (01/11/04). • International Journal of Clinical Pharmacology and Therapeutics. Vol. 46-No. 8/2008 (407-414) • Clinical Therapeutics. Vol 32, No. 4, 2010 GP‐PHARM LIPOSOMES Liposomes are drug carriers formed spontaneously by dispersion of phospolipids in aqueous media. This closed membrane structures can incorporate lipophilic or amphophilic drug into or associated with the lipid bilayer. Stability of the membrane depends on lipid composition and cholesterol content of the liposomal membrane. Summary GP Pharm has expertise using different composition of lipid components for liposome preparation: cationic, anionic, neutral (being used separately or in different ratios). Also expertise obtaining Liposomes through out different sizing technologies such as: microfluidification, extrussion and Sonication. Platform based on liposomes for injection which includes the drug substance and lipochroman (a own proprietary antioxidant product) in the wall of the liposome. Suitable platform to encapsulate cytotoxic compounds to reduce its toxicity or increase its bioavailability. GP Pharm’s own developments • A new patented liposomal formulation of encapsulated Doxorubicin, containing Lipocrhoman EPO 655239 :Sarcodoxome. • Target liposomes Applications Patent application number Priority date References GP Pharm’s developments to third parties ES2186484 B1, ES2259674 T3, ES2072223 B1, ES2154560 B1, ES2189372 T3, ES2130056 B1, ES2162746 B1 ES2186484 B1 (01/07/04), ES2259674 T3, (16/10/06), ES2072223 B1 (06/02/96), ES2154560 B1 (24/09/01), ES2189372 T3 (04/12/02), ES2130056 B1 (01/02/00), ES2162746 B1 (19/12/02) • Liposome Res. 2009;19(4):261-6 CLEAN BIOTEC Phytodesal Summary Applications Patent application number Priority date References Desalina(on method by using salt phytoaccumulators. Cheap and clean phytoremedia(on method to extract salt from soil and water with halophylic plants usefull for animal feed. Saline soils from private and public administra(ons CLEAN BIOTEC Halodepur© Summary Applica-ons Patent applica-on number Priority date References Specific formula for the treatment of hypersaline wastewater by using halophilic bacterial strains Saline wastewaters from meat, fish and pickles industry Spanish trademark Nº 2.941.705 GROUP BIOT Microorganisms from industrial interest. Lac4c fermenta4on. Summary Search, selection and protection of microorganisms from industrial interest in the field of functional food and fermentation. Func4onal food. Applications Patent application number Priority date References 1 BioSeren(a BIOMASSBOOSTER Proprietary Gene-c Engineering Pla2orm to increase biomass yields from microalgae and higher plants and crops Summary Applications Patent application number Priority date References BioMassBooster has discovered a gene BMB – 707 which if properly s-mulated can provoke biomass increases in the double digit magnitude. Selected Microalgae and other higher species by clients are in the process of being engineered in order to become super species capable of yielding significant amounts of biomass and high valued byproducts. • Bioenergy (biodiesel, bioethanol, biogas) • Pharma & cosme-cs industries • Food and Addi-ves industries • Acuiculture • Specialty chemicals • Agrochemicals Patent pending BIOMEDAL, S.L. PROTEO‐STAMPS SIMPLE PURIFICATION, STORAGE AND DELIVERY OF RECOMBINANT PROTEINS Simple technology for the immobiliza4on of recombinant proteins onto membranes. The system can be used with recombinant proteins fused to the poly‐his4dine tag (His‐Tag) or to the choline binding domain LYTAG. Summary Designed for the purifica4on and non‐refrigerated storage (room temperature for several weeks, without integrity or ac4vity loss) and transport of proteins. The system is based on the reversible, affinity absorp4on of the target proteins to different supports, including Ni‐NTA and Ni‐IDE deriva4zed membranes for His‐ Tag fused proteins, as well as membranes with affinity for polypep4des fused to LYTAG. The protein can be easily eluted by the recipient scien4st or technician by using a simple – Economical and convenient, can be used for protein Immobiliza4on/ purifica4on from cell lysates. Applica-ons – The system avoids using stabilizer agents (glycerol, detergents, BSA) that could interfere with the final desired applica4on. – Conven4onal mail envelopes or boxes can be used; with no need for dry or blue ice based delivery systems. – Simple, it only requires two buffers (Immobiliza4on buffer and Elu4on buffer) and a compa4ble membrane support. Patent Applica-on number Priority Date References ES200702475 11/09/2007 BIOMEDAL, S.L. LYTAG TWO‐PHASE RECOMBINANT PROTEIN PURIFICATION SYSTEM BY LYTAG AFFINITY Summary Applica-ons Patent Applica-on number Priority Date The method relies on the affinity of the protein tag LYTAG for one of the two‐ phase components, allowing recombinant protein separa=on and purifica=on from cellular extracts or culture media. In the procedure, the LYTAG‐fused protein is retained in one of the aqueous phases while most of the undesired proteins can be removed by simply discarding the opposite phase. AEer replenishing the system with fresh phase, the protein of interest can be easily recovered in it, with high purity, by reversing its localiza=on with the addi=on of choline, the specific LYTAG ligand. This system is par=cularly well suited for industries and laboratory specialized in protein separa=on and purifica=on, as it is simple, cost efficient, =me saving and highly versa=le for scaling up protein purifica=on process, represen=ng a convenient alterna=ve to solid resins. ES200702504 12/09/2007 Exclusive Licensed to Biomedal S.L by Miguel Hernández University References ‐Maestro B, Velasco I, Cas=llejo I, Arévalo‐Rodríguez M, Cebolla A, Sanz JM. Affinity par==oning of proteins tagged with choline‐binding modules in aqueous two‐phase systems. J Chromatogr A. (2008); 1208:189‐196. BIOMEDAL, S.L. HIS‐TAG TWO PHASE SEPARATION SYSTEM PURIFY RECOMBINANT PROTEINS FUSED TO HIS‐TAG Summary ‐ HIS‐TAG Two Phase Separa2on System is a protein purifica2on system based on the use of two aqueous components. The method relies on the preferen2al par22oning of polyhis2dine tagged proteins in one of the two phase components, allowing recombinant protein separa2on and purifica2on from cellular extracts or culture media. In the procedure. ‐ The His‐tag fused protein is retained in one of the aqueous phases while most of the undesired proteins can be removed by simply discarding the opposite phase. AEer replenishing the system with fresh phase, the protein of interest can be easily recovered in it, with considerable purity, by changing the pH of the system. ‐ This system is par2cularly well suited for industries and laboratories specialized in protein separa2on and purifica2on, as it is simple, cost efficient, 2me saving and highly versa2le for scaling up protein purifica2on processes, represen2ng an alterna2ve good complement to solid resins. Applica-ons Patent Applica-on number P201031724 Priority Date 24/11/2010 References BIOMEDAL, S.L. GLUTENTOX GLUTEN DETECTION METHODS GlutenTox is a family of different prac6cal tools to detect the most immunogenic frac6on of gluten from wheat, rye and barley. Summary The company in collabora6on with University of Sevilla, CSIC and University of Stanford developed two different an6bodies against the highly immunogenic 33‐ mer pep6de of gliadin, called G12 and A1. Based on these an6bodies, Biomedal Diagnos6cs developed a variety of gluten detec6on kit combining G12 and A1 an6bodies, they are specific to the toxic frac6on of gluten . ‐ELISA (Sandwich and Compe66ve) provides Quan6ta6ve results, Detec6on limit of 1.3 ppm, Results in 2 hours, convenient for tes6ng hydrolyzed food and no cross‐ reac6vity with soy or any other safe ingredient. ‐Chromatographic S6cks provide semi‐quan6ta6ve results, detec6on limit 3 ppm. Applica-ons Results in 1 hour. No false nega6ves or posi6ves and no cross‐reac6vity with soy. There is a user‐friendly version that can be used when labeling is absent or unclear to help celiac pa6ents. Detec6on limit >10ppm. ‐ ‐BES+: Biomedal Extrac6on Solu6on , Greater recovery gluten in different types of: ‐ Heat processed matrices ‐ Not heat processed matrices ‐ Hydrolyzed matrices Patent Applica-on number P201031612 Priority Date 03/11/2010 ‐Morón B, et al. Toward the assessment of food toxicity for celiac pa6ents: characteriza6on of monoclonal an6bodies to a main immunogenic gluten pep6de. PLoS One. 2008; 3:e2294 References ‐Morón B, et al. Sensi6ve detec6on of cereal frac6ons that are toxic to celiac disease pa6ents by using monoclonal an6bodies to a main immunogenic wheat pep6de. Am J Clin Nutr. (2008) ; 87:405‐14. ‐Comino I., et al, Diversity in oat poten6al immunogenicity: basis for the selec6on of oat varie6es with no toxicity in celiac disease. Gut. 2011 BIOMEDAL S.L. CASCADE ™ BACTERIAL PROTEIN EXPRESSION SYSTEM CASCADE is a bacterial protein expression system that provides 9ghtly regulated, high‐level expression. The system makes use of linked regulatory circuits to amplify gene expression levels when induced, maintaining low basal expression levels under non‐inducing condi9ons. Summary CASCADE is especially convenient for scaling the produc9on of recombinant proteins. The industrial produc9on of recombinant enzymes, an9gens, biopharmaceu9cals or industrial proteins is highly recommended using CASCADE™ expression system because of its high protein produc9on yield, combined with the fact that the protein expression is also 9ghtly regulated, and can be controlled adding different inducer concentra9ons so the solubility of the protein is facilitated, reducing the risk of inclusion bodies. ‐ Laboratory and large scale recombinant protein Expression/purifica9on: op9miza9on of host, expression systems, and downstream processing with the use of our gene9c technology. Applica7ons – Whole cell biocatalysis: stable assemblage of metabolic pathways. – Programming therapeu9c bacteria expression: an9gen expression and display in aLenuated pathogenic bacteria. – Expression of heteromul9meric proteins. Patent Applica7on number Priority Date References ES2181534 (A1) 22/06/1999 ‐ Royo JL, Moreno‐Ruiz E, Cebolla A., Santero E. Stable long‐term indigo produc9on by overexpression of dioxygenase genes using a chromosomal integrated cascade expression circuit. Journal of Biotechnology. (2005) 116:113‐124. ‐ Royo JL, Becker PD, Camacho EM, Cebolla A, Link C, Santero E, Guzmán CA. In vivo gene regula9on in Salmonella spp. by a salicylate‐dependent control circuit. Nature Methods. (2007), 4:937‐942. ‐ Cebolla, A, Sousa. C V. de Lorenzo. Ra9onal design of a transcrip9onal cascade circuit for amplifica9on of gene expression capacity. Nucleic Acid Research (2001) 29:759‐766. BIOMEDAL S.L. LYTAG TWO‐PHASE RECOMBINANT PROTEIN PURIFICATION SYSTEM BY LYTAG AFFINITY Summary Applica7ons Patent Applica7on number Priority Date The method relies on the affinity of the protein tag LYTAG for one of the two‐ phase components, allowing recombinant protein separa9on and purifica9on from cellular extracts or culture media. In the procedure, the LYTAG‐fused protein is retained in one of the aqueous phases while most of the undesired proteins can be removed by simply discarding the opposite phase. Ader replenishing the system with fresh phase, the protein of interest can be easily recovered in it, with high purity, by reversing its localiza9on with the addi9on of choline, the specific LYTAG ligand. This system is par9cularly well suited for industries and laboratory specialized in protein separa9on and purifica9on, as it is simple, cost efficient, 9me saving and highly versa9le for scaling up protein purifica9on process, represen9ng a convenient alterna9ve to solid resins. ES200702504 12/09/2007 Exclusive Licensed to Biomedal S.L by Miguel Hernández University References ‐Maestro B, Velasco I, Cas9llejo I, Arévalo‐Rodríguez M, Cebolla A, Sanz JM. Affinity par99oning of proteins tagged with choline‐binding modules in aqueous two‐phase systems. J Chromatogr A. (2008); 1208:189‐196. BIOMEDAL S.L. PROTE‐STAMPS SIMPLE PURIFICATION, STORAGE AND DELIVERY OF RECOMBINANT PROTEINS Simple technology for the immobiliza9on of recombinant proteins onto membranes. The system can be used with recombinant proteins fused to the poly‐his9dine tag (His‐Tag) or to the choline binding domain LYTAG. Summary Designed for the purifica9on and non‐refrigerated storage (room temperature for several weeks, without integrity or ac9vity loss) and transport of proteins. The system is based on the reversible, affinity absorp9on of the target proteins to different supports, including Ni‐NTA and Ni‐IDE deriva9zed membranes for His‐ Tag fused proteins, as well as membranes with affinity for polypep9des fused to LYTAG. The protein can be easily eluted by the recipient scien9st or technician by using a simple – Economical and convenient, can be used for protein Immobiliza9on/ purifica9on from cell lysates. Applica7ons – The system avoids using stabilizer agents (glycerol, detergents, BSA) that could interfere with the final desired applica9on. – Conven9onal mail envelopes or boxes can be used; with no need for dry or blue ice based delivery systems. – Simple, it only requires two buffers (Immobiliza9on buffer and Elu9on buffer) and a compa9ble membrane support. Patent Applica7on number Priority Date References ES200702475 11/09/2007 BIOMEDAL S.L. HIS‐TAG TWO PHASE SEPARATION SYSTEM PURIFY RECOMBINANT PROTEINS FUSED TO HIS‐TAG Summary ‐ HIS‐TAG Two Phase Separa9on System is a protein purifica9on system based on the use of two aqueous components. The method relies on the preferen9al par99oning of polyhis9dine tagged proteins in one of the two phase components, allowing recombinant protein separa9on and purifica9on from cellular extracts or culture media. In the procedure. ‐ The His‐tag fused protein is retained in one of the aqueous phases while most of the undesired proteins can be removed by simply discarding the opposite phase. Ader replenishing the system with fresh phase, the protein of interest can be easily recovered in it, with considerable purity, by changing the pH of the system. Applica7ons ‐ This system is par9cularly well suited for industries and laboratories specialized in protein separa9on and purifica9on, as it is simple, cost efficient, 9me saving and highly versa9le for scaling up protein purifica9on processes, represen9ng an alterna9ve good complement to solid resins. Patent Applica7on number P201031724 Priority Date 24/11/2010 References BIOMASLINIC S.L. Method for obtaining maslinic acid and hydroxitirosol from olive byproducts. Summary Applications Patent application number Priority date References BIOMASLINIC S.L. is a biotechnology company that develops patents for the use of products derived from olive groves (maslinic acid, hydroxitirosol, elenolic acid…). It is dedicated to the industrial extraction of these products and it is focused on the research and development of olive grove byproducts that can be used in sectors related to diet and health improvement. Production and supply of MASLINIC ACID and HYDROXITIROSOL for industries related to diet, pharmacy, oil, animal diet, etc. Research, discovery and development of methodology for obtaining other substances derived with potential health benefits. ES 2 111 498 B1 ES 2 291 111 A1 25/07/1996 17/02/2006 ARQUEBIO Recombinant proteins for gene therapy Recombinant proteins from microbial origin as a proof of concept for gene therapy Summary Applica(ons in pharma and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Chemical bioconjuga0on of biopolymers with APIs Summary Chemical pla7orm for the bioconjuga(on of ac(ve pharmaceu(cal ingredients with biopolymers of microbial origin, for drug delivery end uses. Applica(ons in pharma and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Hyaluronic acid of microbial origin pla2orm Summary Naturally occurring or enzyma(cally modified hyaluronic acid and hyaluronic acid deriva(ves from microbial origin, using wild or recombinant microbial strains. Applica(ons in cosme(cs and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Mul$func$onal proteins for healthcare end uses Mul(func(onal proteins from recombinant microbial origin for healthcare end uses. Summary Applica(ons in pharma and cosme(cs Applications Patent application number Priority date References On process ARQUEBIO Mul$func$onal proteins for drug delivery Mul(func(onal proteins from recombinant microbial origin for drug delivery end uses. Summary Applica(ons in pharma and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Chem to Biotech screening pla,orm for microbial and enzyma4c reac4ons for bioprocess applica4ons Summary Applications Patent application number Priority date References Bioconversion screening pla,orm tool C2B ® (Chem to Biotech) of Arquebio is a system based in the use of enzymes and microorganisms for the fast, cheap and reliable evalua4on of the capacity to carry on chemical reac4ons upon substrates of well defined structure,using biological methods . Applica4ons in fine chemical synthesis for pharmaceu4cal, cosme4c , agrofood and chemical companies On process ARQUEBIO Polyhydroxyalkanoates of microbial origin pla7orm Summary Natural occurring or enzyma(cally modified Polyhydroxyalkanoates from microbial origin , using wild or recombinant microbial strains. Applica(ons in cosme(cs and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Modified biopolymers for cosme1c applica1ons Enzyma(cally modified biopolymers from microbial origin , using wild or recombinant microbial strains. Summary Applica(ons in cosme(cs and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Halomuccines for cosme/c applica/ons Summary Naturally occurring or enzyma(cally modified halomuccines from halofilic bacteria origin , using wild or recombinant microbial strains. Applica(ons in cosme(cs and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Exopolysaccharides for cosme2c applica2ons Summary Naturally occurring or enzyma(cally modified exopolysaccharides from several microbial origins including Archaea , using wild or recombinant microbial strains. Applica(ons in cosme(cs and drug delivery Applications Patent application number Priority date References On process ARQUEBIO Microbial resolu-on of racemic compounds Summary Applications Patent application number Priority date References High performance bioprocess esterifica-ons for the resolu-on of racemic compounds, on ac-ve pharmaceu-cal ingredients, polymers and high valued molecules, instead of using chemical synthesis. Enzymes and microorganisms can be used free or immobilized, and the process can recover the non‐desired enan-omer to convert it into the targeted one. Applica-ons in fine chemical synthesis for the resolu-on of racemic compounds or the recovery of non‐desired enan-omers . On process ARQUEBIO Microbial oxyda-on of methylnaphtalenes Summary Applications Patent application number Priority date References High performance bioprocess for the oxyda-on of methyl end groups in naphtalene molecules, using enzymes or microorganisms, free or immobilized. Applica-ons in fine chemical synthesis for the oxyda-on of methyl end groups in naphtalene molecules. On process ARQUEBIO Microbial oxyda-on of anthraquinones Summary Applications Patent application number Priority date References High performance bioprocess for the oxyda-on of methyl end groups in anthraquinone molecules, using enzymes or microorganisms, free or immobilized. Applica-ons in fine chemical synthesis for the oxyda-on of methyl end groups in anthraquinone molecules. On process ARQUEBIO Microbial modifica-on of tritherpenes Summary Applications Patent application number Priority date References High performance bioprocess for the modifica-on of end groups in tritherpene molecules, from methyl to acid en groups, using enzymes or microorganisms, free or immobilized. Applica-ons in fine chemical synthesis for the modifica-on of end groups in tritherpene molecules. On process ARQUEBIO Biocatalysis pla,orm for esterifica2on of organic compounds Summary Applications Patent application number Priority date References High performance stereospecific bioprocess reac2ons using lipases for the esterifica2on of polar and non‐polar alcohols and acids on ac2ve pharmaceu2cal ingredients, polymers and high valued molecules, instead of using chemical synthesis. Enzymes and microorganisms can be used free or immobilized. Applica2ons in fine chemicals or polymer synthesis, and in the resolu2on of enan2omeric mixtures via genera2on of esters . On process ARQUEBIO Biocatalysis pla,orm for aldole condensa3ons Summary Applications Patent application number Priority date References High performance bioprocess reac3ons using liases for aldole condensa3ons , on ac3ve pharmaceu3cal ingredients, polymers and high valued molecules, instead of using chemical synthesis. Enzymes and microorganisms can be used free or immobilized. Applica3ons in fine chemicals or polymer synthesis, for the genera3on of C‐C bonds. On process ARQUEBIO Biocatalysis pla,orm for oxyda2on of methyl groups in aroma2c substances Summary Applications Patent application number Priority date References High performance bioprocess reac2ons using oxoreductases for the oxyda2on of methyl end groups in aroma2c compounds to alcohol, aldehyde and acid end groups,on ac2ve pharmaceu2cal ingredients, polymers and high valued molecules, instead of using chemical synthesis. Enzymes and microorganisms can be used free or immobilized. Applica2ons in fine chemicals or polymer synthesis, and for the func2onaliza2on of methyl end groups. On process
